A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Trial Profile

A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2016

At a glance

  • Drugs Idelalisib (Primary) ; Bendamustine; Bortezomib; Chlorambucil; Everolimus; Fludarabine; Lenalidomide; Ofatumumab; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 214177 and 35836) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Jun 2015 Long-term results in patients with chronic lymphocytic leukaemia presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top